Tamara Z Vern-Gross1, Jane E Schreiber1, Alberto Broniscer1, Shengjie Wu1, Xiaoping Xiong1, Thomas E Merchant1. 1. Department of Radiation Oncology, University of Florida Proton Therapy Institute, Jacksonville, Florida (T.Z.V.-G.); Department of Psychology, St. Jude Children's Research Hospital, Memphis, Tennessee (J.E.S.); Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee (A.B.); Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee (S.W., X.X.); Department of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee (T.E.M.).
Abstract
BACKGROUND: A phase II trial of conformal radiotherapy (CRT) for pediatric high-grade glioma (HGG) was performed to evaluate disease control and late effects. METHODS: Between July 1997 and January 2003, 34 pediatric patients (median age, 13.2 ± 6.7 years) with HGG were enrolled on an International Commission on Radiation Units and Measurements Report 50-compliant prospective trial using CRT with a 2 cm clinical target volume margin. Baseline and serial evaluations were performed to assess functional outcomes. RESULTS: Median follow-up for the entire group was 18 months (range, 2-134 months). Twenty (58.8%) patients developed local progression, and 6 (17.6%) patients developed distant progression. Progression-free and overall survival at 10 years were 18.8% ± 6.9% and 16.8% ± 6.5%, respectively. At baseline, 40% of patients evaluated for intelligence quotient (IQ) scored below 85. Measures of cognitive function obtained during the first 12 months fit a mixed model with a quadratic function. The relationship between IQ and time was -1.1883 points/month for the linear term and 0.07728 points/month for the quadratic term (P = .0454). IQ decreased between baseline and 6 months and then increased slightly through 12 months. The opposite was found for (all P values of the quadratic term) activities of daily living (P = .0155), socialization (P = .0049), and the composite score (P = .0257) of adaptive behavior. CONCLUSION: CRT using a 2 cm clinical target volume margin in pediatric HGG demonstrated tumor control comparable to conventional radiation therapy. Disrupted cognitive and adaptive behavioral functioning were present at baseline and throughout the course of disease.
BACKGROUND: A phase II trial of conformal radiotherapy (CRT) for pediatric high-grade glioma (HGG) was performed to evaluate disease control and late effects. METHODS: Between July 1997 and January 2003, 34 pediatric patients (median age, 13.2 ± 6.7 years) with HGG were enrolled on an International Commission on Radiation Units and Measurements Report 50-compliant prospective trial using CRT with a 2 cm clinical target volume margin. Baseline and serial evaluations were performed to assess functional outcomes. RESULTS: Median follow-up for the entire group was 18 months (range, 2-134 months). Twenty (58.8%) patients developed local progression, and 6 (17.6%) patients developed distant progression. Progression-free and overall survival at 10 years were 18.8% ± 6.9% and 16.8% ± 6.5%, respectively. At baseline, 40% of patients evaluated for intelligence quotient (IQ) scored below 85. Measures of cognitive function obtained during the first 12 months fit a mixed model with a quadratic function. The relationship between IQ and time was -1.1883 points/month for the linear term and 0.07728 points/month for the quadratic term (P = .0454). IQ decreased between baseline and 6 months and then increased slightly through 12 months. The opposite was found for (all P values of the quadratic term) activities of daily living (P = .0155), socialization (P = .0049), and the composite score (P = .0257) of adaptive behavior. CONCLUSION: CRT using a 2 cm clinical target volume margin in pediatric HGG demonstrated tumor control comparable to conventional radiation therapy. Disrupted cognitive and adaptive behavioral functioning were present at baseline and throughout the course of disease.
Authors: Thomas E Merchant; Olga Goloubeva; David L Pritchard; M Waleed Gaber; Xiaoping Xiong; Robert K Danish; Robert H Lustig Journal: Int J Radiat Oncol Biol Phys Date: 2002-04-01 Impact factor: 7.038
Authors: R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond Journal: J Neurooncol Date: 1989-07 Impact factor: 4.130
Authors: Kimberly P Raghubar; Jessica Orobio; M Douglas Ris; Andrew M Heitzer; Alexandra Roth; Austin L Brown; M Fatih Okcu; Murali Chintagumpala; David R Grosshans; Arnold C Paulino; Anita Mahajan; Lisa S Kahalley Journal: Pediatr Blood Cancer Date: 2019-05-27 Impact factor: 3.167
Authors: Alexandra K Roth; M Douglas Ris; Jessica Orobio; Judy Xue; Anita Mahajan; Arnold C Paulino; David Grosshans; M Fatih Okcu; Murali Chintagumpala; Lisa S Kahalley Journal: Pediatr Blood Cancer Date: 2019-11-17 Impact factor: 3.167
Authors: Benjamin Farnia; Nancy Philip; Rola H Georges; Mary Frances McAleer; Matthew Palmer; Jinzhong Yang; Pamela K Allen; Mary K Martel; Anita Mahajan; Susan L McGovern Journal: Int J Part Ther Date: 2016-08-29
Authors: Asim K Bag; Melissa N Wing; Noah D Sabin; Scott N Hwang; Gregory T Armstrong; Yuanyuan Han; Yimei Li; Scott E Snyder; Giles W Robinson; Ibrahim Qaddoumi; Alberto Broniscer; John T Lucas; Barry L Shulkin Journal: J Nucl Med Date: 2021-08-26 Impact factor: 10.057
Authors: Aaron Y Mochizuki; Isaura M Frost; Melina B Mastrodimos; Ashley S Plant; Anthony C Wang; Theodore B Moore; Robert M Prins; Paul S Weiss; Steven J Jonas Journal: ACS Chem Neurosci Date: 2017-12-27 Impact factor: 4.418